Presentation is loading. Please wait.

Presentation is loading. Please wait.

Humanized anti–IFN-γ (HuZAF) in the treatment of psoriasis

Published byUlla Astrid Bergman Modified over 5 years ago

Similar presentations

Presentation on theme: "Humanized anti–IFN-γ (HuZAF) in the treatment of psoriasis"— Presentation transcript:

1 Humanized anti–IFN-γ (HuZAF) in the treatment of psoriasis
Jamie L. Harden, PhD, Leanne M. Johnson-Huang, PhD, Maria Francesca Chamian, MD, Edmund Lee, MD, Tillman Pearce, MD, Craig L. Leonardi, MD, Asifa Haider, PhD, Michelle A. Lowes, MD, PhD, James G. Krueger, MD, PhD  Journal of Allergy and Clinical Immunology  Volume 135, Issue 2, Pages e3 (February 2015) DOI: /j.jaci Copyright © 2014 American Academy of Allergy, Asthma & Immunology Terms and Conditions

2 Fig 1 Effect of a single dose of HuZAF (10 mg/kg) for treatment of psoriasis. H&E (A) and K16 (B) staining of a responding patient. C, PASI scores for 2 patients. D, Epidermal thickness in baseline nonlesional (NL) and lesional skin (LS), as well as day 29 posttreatment. E, CD3+ T cells quantified by immunohistology. F, Inflammatory gene expression as determined by quantitative RT-PCR. G, Staining of HuZAF using AF2id. All histology images shown at same magnification; bar = 10 μm. Each colored line represents a single patient. H&E, Hematoxylin and eosin. Journal of Allergy and Clinical Immunology  , e3DOI: ( /j.jaci ) Copyright © 2014 American Academy of Allergy, Asthma & Immunology Terms and Conditions

3 Fig 2 Results of a multiple-dose regimen of HuZAF in the treatment of psoriasis. A, PASI scores in patients receiving 4 HuZAF infusions (arrows indicate the administration of treatment). B and C, Inflammatory gene expression as determined by quantitative RT-PCR, for each patient in nonlesional (NL), lesional (LS), and posttreatment LS skin. Each colored line represents a single patient. Journal of Allergy and Clinical Immunology  , e3DOI: ( /j.jaci ) Copyright © 2014 American Academy of Allergy, Asthma & Immunology Terms and Conditions

4 Fig E1 Gene expression of single dose HuZAF (10 mg/kg) study. Data from individiual patients are pooled and displayed here. Error bars = SE. Data analyzed using paired t test. ∗P < .05. Journal of Allergy and Clinical Immunology  , e3DOI: ( /j.jaci ) Copyright © 2014 American Academy of Allergy, Asthma & Immunology Terms and Conditions

5 Fig E2 Gene expression of multi-dose HuZAF trial. Inflammatory gene expression determined in biopsies of basline NL and LS, as well as post-treatment. Data from 10 individual patients (A) and combined data (mean) from all 10 patients (B); error bars = SE. Data analyzed using paired t test. ∗P < .05, ∗∗P < .01, and ∗∗∗P < .001. Journal of Allergy and Clinical Immunology  , e3DOI: ( /j.jaci ) Copyright © 2014 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Download ppt "Humanized anti–IFN-γ (HuZAF) in the treatment of psoriasis"

Similar presentations

A bioinformatics approach to identify patients with symptomatic peanut allergy using peptide microarray immunoassay Jing Lin, PhD, Francesca M. Bruni,

A bioinformatics approach to identify patients with symptomatic peanut allergy using peptide microarray immunoassay Jing Lin, PhD, Francesca M. Bruni,
Jonathan A. Bernstein, MD, David M. Lang, MD, David A. Khan, MD 

Jonathan A. Bernstein, MD, David M. Lang, MD, David A. Khan, MD 
Anti–IL-23A mAb BI 655066 for treatment of moderate-to-severe psoriasis: Safety, efficacy, pharmacokinetics, and biomarker results of a single-rising-dose,

Anti–IL-23A mAb BI for treatment of moderate-to-severe psoriasis: Safety, efficacy, pharmacokinetics, and biomarker results of a single-rising-dose,
Cyclosporine in patients with atopic dermatitis modulates activated inflammatory pathways and reverses epidermal pathology  Saakshi Khattri, MD, Avner.

Cyclosporine in patients with atopic dermatitis modulates activated inflammatory pathways and reverses epidermal pathology  Saakshi Khattri, MD, Avner.
Residual genomic profile after cyclosporine treatment may offer insights into atopic dermatitis reoccurrence  Mariya Rozenblit, BA, Mayte Suarez-Farinas,

Residual genomic profile after cyclosporine treatment may offer insights into atopic dermatitis reoccurrence  Mariya Rozenblit, BA, Mayte Suarez-Farinas,
Topical application of a vitamin D3 analogue and corticosteroid to psoriasis plaques decreases skin infiltration of TH17 cells and their ex vivo expansion 

Topical application of a vitamin D3 analogue and corticosteroid to psoriasis plaques decreases skin infiltration of TH17 cells and their ex vivo expansion 
Clarification concerning amoxicillin skin testing

Clarification concerning amoxicillin skin testing
An IL-17–dominant immune profile is shared across the major orphan forms of ichthyosis  Amy S. Paller, MD, MS, Yael Renert-Yuval, MD, Maria Suprun, MPH,

An IL-17–dominant immune profile is shared across the major orphan forms of ichthyosis  Amy S. Paller, MD, MS, Yael Renert-Yuval, MD, Maria Suprun, MPH,
Santa Jeremy Ono, BA, PhD, Mark B. Abelson, MD 

Santa Jeremy Ono, BA, PhD, Mark B. Abelson, MD 
Intrinsic atopic dermatitis shows similar TH2 and higher TH17 immune activation compared with extrinsic atopic dermatitis  Mayte Suárez-Fariñas, PhD,

Intrinsic atopic dermatitis shows similar TH2 and higher TH17 immune activation compared with extrinsic atopic dermatitis  Mayte Suárez-Fariñas, PhD,
Alefacept (lymphocyte function-associated molecule 3/IgG fusion protein) treatment for atopic eczema  Dagmar Simon, MD, Jennifer Wittwer, MD, Ganna Kostylina,

Alefacept (lymphocyte function-associated molecule 3/IgG fusion protein) treatment for atopic eczema  Dagmar Simon, MD, Jennifer Wittwer, MD, Ganna Kostylina,
Inflammatory marker analysis in psoriatic skin under topical phosphodiesterase 4 inhibitor treatment  Lennart M. Roesner, PhD, Petra Kienlin, Gabriele.

Inflammatory marker analysis in psoriatic skin under topical phosphodiesterase 4 inhibitor treatment  Lennart M. Roesner, PhD, Petra Kienlin, Gabriele.
Dupilumab improves the molecular signature in skin of patients with moderate-to-severe atopic dermatitis  Jennifer D. Hamilton, PhD, Mayte Suárez-Fariñas,

Dupilumab improves the molecular signature in skin of patients with moderate-to-severe atopic dermatitis  Jennifer D. Hamilton, PhD, Mayte Suárez-Fariñas,
Topical application of a vitamin D3 analogue and corticosteroid to psoriasis plaques decreases skin infiltration of TH17 cells and their ex vivo expansion 

Topical application of a vitamin D3 analogue and corticosteroid to psoriasis plaques decreases skin infiltration of TH17 cells and their ex vivo expansion 
Anti–IL-23A mAb BI 655066 for treatment of moderate-to-severe psoriasis: Safety, efficacy, pharmacokinetics, and biomarker results of a single-rising-dose,

Anti–IL-23A mAb BI for treatment of moderate-to-severe psoriasis: Safety, efficacy, pharmacokinetics, and biomarker results of a single-rising-dose,
Is 9 more than 2 also in allergic airway inflammation?

Is 9 more than 2 also in allergic airway inflammation?
Jonathan A. Bernstein, MD, David M. Lang, MD, David A. Khan, MD 

Jonathan A. Bernstein, MD, David M. Lang, MD, David A. Khan, MD 
IL-17A is essential for cell activation and inflammatory gene circuits in subjects with psoriasis  James G. Krueger, MD, Scott Fretzin, MD, Mayte Suárez-Fariñas,

IL-17A is essential for cell activation and inflammatory gene circuits in subjects with psoriasis  James G. Krueger, MD, Scott Fretzin, MD, Mayte Suárez-Fariñas,
Pathergy response to skin prick testing

Pathergy response to skin prick testing
Reversal of atopic dermatitis with narrow-band UVB phototherapy and biomarkers for therapeutic response  Suzanne Tintle, BS, Avner Shemer, MD, Mayte Suárez-Fariñas,

Reversal of atopic dermatitis with narrow-band UVB phototherapy and biomarkers for therapeutic response  Suzanne Tintle, BS, Avner Shemer, MD, Mayte Suárez-Fariñas,

Similar presentations

Ads by Google